The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats

Vascular Pharmacology

Volumn 54, Issue 1-2, 2011, Pages 36-43

  Wang, Yan ^a   Zhang, MingSheng ^a   Liu, YunFeng ^a   Liu, Yu ^a   Chen, Min ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine(ADMA); Dimethylarginine dimethylaminohydrolase (DDAH); Nebivolol; Protein arginine methyltransferase (PRMT); Spontaneously hypertensive rats (SHR)

Indexed keywords

ATENOLOL; DIMETHYLARGININASE; DIMETHYLARGININASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; RAT; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; WISTAR KYOTO RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AMIDOHYDROLASES; ANIMALS; AORTA; ARGININE; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; ETHANOLAMINES; HYPERTENSION; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN-ARGININE N-METHYLTRANSFERASES; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

EID: 79952622857     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.12.001     Document Type: Article

References (32)

1. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1455-1459.
2. Agabiti-Rosei E., Porteri E., Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009, 5(1):353-360.
3. Ardigo D., Stuehlinger M., Franzini L., Valtuena S., Piatti P.M., Pachinger O., Reaven G.M., Zavaroni I. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur. J. Clin. Invest. 2007, 37:263-269.
4. Bakris G.L., Basile J.N., Giles T.D., Taylor A.A. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am. J. Med. 2010, 123(7 Suppl 1):S2-S8. Jul.
5. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., Cooke J.P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
6. Cable D.G., Celotto A.C., Evora P.R., et al. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects. Med. Sci. Monit. 2009, 15(9):BR248-BR253. Sep.
7. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler. Thromb. Vasc. Biol. 2000, 20(9):2032-2037. Sep.
8. Garbin U., Pasini A.F., Stranieri C., Manfro S., Boccioletti V., Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol. Res. 2007, 56(6):515-521. Dec.
9. Giustarini D., Rossi R., Milzani A., Dalle-Donne I. Nitrite and nitrate measurement by Griess reagent in human plasma: evaluation of interferences and standardization. Methods Enzymol. 2008, 440:361-380.
10. Hillebrand U., Lang D., Telgmann R.G., Hagedorn C., Reuter S., Kliche K., Stock C.M., Oberleithner H., Pavenstädt H., Büssemaker E., Hausberg M. Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study. J. Hypertens. 2009, 27(3):517-526. Mar.
11. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
12. Karagiannis A., Athyros V.G., Papageorgiou A., Tziomalos K., Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension?. Hellenic J Cardiol. 2006, 47(5):298-307. Sep-Oct.
13. Li J., Zhou Z., Jiang D.J., Li D., Tan B., Liu H., Li Y.J. Reduction of NO- and EDHF-mediated vasodilatation in hypertension: role of asymmetric dimethylarginine. Clin. Exp. Hypertens. 2007, 29(7):489-501. Oct.
14. Li H., Cao R., Wasserloos K.J., Bernal P., Liu Z.Q., Pitt B.R., St Croix C.M. Nitric oxide and zinc homeostasis in pulmonary endothelium. Ann. NY Acad. Sci. 2010, 1203:73-78. Aug.
15. Lüscher T.F., Spieker L.E., Noll G., Cosentino F. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. J. Cardiovasc. Pharmacol. 2001, 38(Suppl 3):S3-S11. Dec.
16. Miller V.M., Barber D.A. Modulation of endothelium-derived nitric oxide in canine femoral veins. Am. J. Physiol. Heart Circ. Physiol. 1996, 271:H668-H673.
17. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141-1146.
18. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., Oelze M., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90:E58-E65.
19. Myatt L., Brockman D.E., Langsdon G., Pollock J.S. Constitutive calcium-dependent isoform of nitric oxide synthase in the human placental villous vascular tree. Placenta 1993, 14:373-383.
20. Okubo K., Hayashi K., Wakino S., Matsuda H., Kubota E., Honda M., Tokuyama H., Yamamoto T., Kajiya F., Saruta T. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens. Res. 2005, 28:181-189.
21. Pasini A.F., Garbin U., Stranieri C., Boccioletti V., Mozzini C., Manfro S., Pasini A., Cominacini M., Cominacini L. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am. J. Hypertens. 2008, 21(11):1251-1257. Nov.
22. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996, 97:1916-1923.
23. Rodrigo M.C., Martin D.S., Redetzke R.A., Eyster K.M. A method for the extraction of high quality RNA and protein from single small samples of arteries and veins preserved in RNAlater. J. Pharmacol. Toxicol. Methods 2002, 47(2):87-92.
24. Scalera F., Borlak J., Beckmann B., Martens-Lobenhoffer J., Thum T., Täger M., Bode-Böger S.M. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler. Thromb. Vasc. Biol. 2004, 24(10):1816-1822. Oct.
25. Segarra G., Medina P., Ballester R.M., et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999, 30:2206-2211.
26. Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C.B., Sudano I., Salvetti A., Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C.B., Sudano I., Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995, 91(7):1981-1987. Apr 1.
27. Tsikas D., Böger R.H., Bode-Böger S.M., Gutzki F.M., JC Frölich Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J. Chromatogr. B 1994, 661:185-191.
28. Tzemos N., Lim P.O., MacDonald T.M. Nebivolol reverses endothelial dysfunction in essential hypertension a randomized, double blind crossover study. Circulation 2001, 104:511-514.
29. Ueda S., Yamagishi S., Matsumoto Y., Fukami K., Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin. Exp. Nephrol. 2007, 11(2):115-121. Jun.
30. Vallance P., Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 2004, 24(6):1023-1030. Jun.
31. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
32. Wang Y., Zhang M., Liu Y., et al. Neither K+channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries. J. Cardiovasc. Pharmacol. Ther. 2009, 14(4):332-338.